---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-24-035806"
form_type: "8-K"
ticker: "NRXP"
cik: "0001719406"
company_name: "NRX Pharmaceuticals, Inc."
filed_at: "2024-11-20T23:59:59+00:00"
generated_at: "2026-05-29T22:01:15.415637+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# NRx Pharmaceuticals appoints Michael Abrams as permanent CFO, base salary $325,000

## Summary
- Michael Abrams appointed CFO effective Nov 18, 2024, succeeding interim CFO Richard Narido.
- Base salary $325,000; initially 50% until Qualified Financing or Feb 1, 2025.
- Granted 50,000 stock options under 2021 Omnibus Incentive Plan, vesting over three years.
- Abrams previously CFO at Arch Therapeutics, RiseIT Solutions, and FitLife Brands.
- Employment agreement includes non-compete, non-solicitation, and severance provisions.

## SEC filing metadata
- accession: 0001437749-24-035806
- form_type: 8-K
- ticker: NRXP
- cik: 0001719406
- company_name: NRX Pharmaceuticals, Inc.
- filed_at: 2024-11-20T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 1.01, 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1719406/000143774924035806/0001437749-24-035806-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1719406/000143774924035806/nrxp20241120_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-24-035806
- JSON: https://secwatch.observer/filing/0001437749-24-035806.json
- Plain text: https://secwatch.observer/filing/0001437749-24-035806.txt

## Key facts
- Executive change
  Richard Narido changed role as Interim Chief Financial Officer at NRX Pharmaceuticals, Inc..
  - Action: succeeded
  - Role: Interim Chief Financial Officer
  source text: Mr. Abrams succeeds Interim Chief Financial Officer Richard Narido, who will continue to support the Company’s financial function and other projects.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1719406/000143774924035806/0001437749-24-035806-index.htm
- Executive change
  Michael Abrams was appointed as Chief Financial Officer at NRX Pharmaceuticals, Inc..
  - Action: appointed
  - Role: Chief Financial Officer
  source text: On November 18, 2024, NRx Pharmaceuticals, Inc. (the “ Company ”) issued a press release announcing the appointment of Michael Abrams as the Chief Financial Officer of the Company.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1719406/000143774924035806/0001437749-24-035806-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.